The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials.
Publication
, Journal Article
O'Connor, CM; Gattis, WA; Ryan, TJ
Published in: Am Heart J
April 2000
Duke Scholars
Published In
Am Heart J
DOI
ISSN
0002-8703
Publication Date
April 2000
Volume
139
Issue
4
Start / End Page
S143 / S154
Location
United States
Related Subject Headings
- Treatment Outcome
- Survival Analysis
- Reproducibility of Results
- Humans
- Clinical Trials, Phase III as Topic
- Clinical Trials, Phase II as Topic
- Cardiovascular System & Hematology
- Cardiovascular Agents
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
Citation
APA
Chicago
ICMJE
MLA
NLM
O’Connor, C. M., Gattis, W. A., & Ryan, T. J. (2000). The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials. Am Heart J, 139(4), S143–S154. https://doi.org/10.1016/s0002-8703(00)90062-0
O’Connor, C. M., W. A. Gattis, and T. J. Ryan. “The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials.” Am Heart J 139, no. 4 (April 2000): S143–54. https://doi.org/10.1016/s0002-8703(00)90062-0.
O’Connor CM, Gattis WA, Ryan TJ. The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials. Am Heart J. 2000 Apr;139(4):S143–54.
O’Connor, C. M., et al. “The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials.” Am Heart J, vol. 139, no. 4, Apr. 2000, pp. S143–54. Pubmed, doi:10.1016/s0002-8703(00)90062-0.
O’Connor CM, Gattis WA, Ryan TJ. The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials. Am Heart J. 2000 Apr;139(4):S143–S154.
Published In
Am Heart J
DOI
ISSN
0002-8703
Publication Date
April 2000
Volume
139
Issue
4
Start / End Page
S143 / S154
Location
United States
Related Subject Headings
- Treatment Outcome
- Survival Analysis
- Reproducibility of Results
- Humans
- Clinical Trials, Phase III as Topic
- Clinical Trials, Phase II as Topic
- Cardiovascular System & Hematology
- Cardiovascular Agents
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services